RECOMBINANT VACCINE MARKET ANALYSIS

Recombinant Vaccine MarketSize and Trends

Global recombinant vaccines market is estimated to be valued at US$ 1,116.1 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

Figure 1.Global Recombinant Vaccines Market Share (%), by Disease Type, 2022

Increasing incidence of zoonotic diseases and emerging technologies for developing vaccines are expected to drive growth of the recombinant vaccines market

Increasing incidence of zoonotic diseases and emerging technologies for developing vaccines are expected to drive growth of the recombinant vaccines market. For instance, according to the data provided by Centers for Disease Control and Prevention report 2022, a total of 4,702 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2021, and May 28, 2022 in the U.S.

Figure 2.Global Recombinant Vaccines Market Share (%), by Region, 2022

Increasing investments and research and development activities for the development of new vaccines are expected to drive the market growth during the forecast period.

Increasing research and development activities by the key players in market for developing recombinant vaccines is expected to drive the market growth over the forecast period. For instance, in February 2021, Sanofi, a multinational healthcare company, and GSK plc., a multinational pharmaceutical company, announced the initiation of a new phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate